Welcome to the OPtimisation of Peri-operaTive CardIovascular Management to Improve Surgical outcomE II (OPTIMISE II) trial.
The OPTIMISE II trial is an international, multi-centre, pragmatic, randomised controlled trial with an open study group allocation, to determine whether cardiac output-guided fluid therapy, with a low dose inotrope infusion is clinically effective when compared to usual care in patients undergoing major gastrointestinal surgery.
OPTIMISE II is a global trial, which launched in January 2017, with over 30 participating centres in Australia, Canada, Germany, Jordan, Poland, Romania, Spain, Switzerland, US and the UK. With more sites opening, recruitment is steadily increasing - thank you to all of our local investigators for their help and support.
This website will continue to be the central communication hub for all aspects of the trial. We will continue to add more information as the study progresses. Please complete an expression of interest here if you would like your hospital to be considered as an OPTIMISE II recruitment site. Please contact us if you have any queries, and follow us on twitter @OPTIMISE2trial for further progress updates.
The OPTIMISE II trial team
Last updated - 2017-10-16